Enso Ventures backs Galera Therapeutics

By Iris Dorbian — 1 week ago

Malvern, Pennsylvania-based Galera Therapeutics, a developer of new treatments for cancer patients, has secured $5 million in funding from Enso Ventures. This capital infusion brings Galera’s Series B funding total to $42 million. Galera’s other investors are New Enterprise Associates, Novartis Venture Fund, Novo Ventures, Correlation Ventures and Galera Angels.

Continue

ObsEva racks up $60 mln Series B

By Iris Dorbian — 3 months ago

Swiss biopharmaceutical company ObsEva, a developer of drugs that focus on “serious conditions compromising pregnancy from conception to birth,” has raised $60 million in Series B funding. The investors included HBM Healthcare Investments, New Enterprise Associates, OrbiMed, Rock Springs Capital, Sofinnova Partners, Sofinnova Ventures, Novo Ventures and MS Ventures. In addition to the funding, Ed Mathers of NEA has been added to ObsEva’s board of directors. Leerink Partners LLC was the advisor on the funding.

Continue

Galera Therapeutics pulls in $37 mln Series B

By Iris Dorbian — 4 months ago

Malvern, Pennsylvania-based Galera Therapeutics, a biotech company focused on treating cancer patients, has closed $37 million in Series B funding. Novo Ventures led the round with participation from previous backers New Enterprise Associates, Novartis Venture Fund, Correlation Ventures and Galera Angels. In conjunction with the funding, Dr. Thomas Dyrberg, a managing partner of Novo Ventures, has been added to Galera’s board of directors.

Continue

Corvus Pharmaceuticals rakes in $75 mln Series B

By Iris Dorbian — 4 months ago

Burlingame, California-based Corvus Pharmaceuticals, a biopharmaceutical company focused on treating cancer, has raised $75 million in Series B funding. Rock Springs Capital Management led the round with participation from other investors that included Fidelity Management and Research Company, Blackrock, Roche Venture Fund, Cormorant Asset Management, venBio Select, Cowen Private Investments, Orbimed, Novo Ventures and Adams Street Partners. Cowen and Company advised Corvus on the transaction.

Continue

Ra Pharmaceuticals racks up $58.5 mln Series B

By Iris Dorbian — 7 months ago

Cambridge, Massachusetts-based biotech company Ra Pharmaceuticals has closed $58.5 million in Series B funding. RA Capital Management, Novo Ventures and Lightstone Ventures led the round with participation from other investors that included Rock Springs Capital Limulus Venture Partners, New Enterprise Associates, Novartis Venture Fund, Morgenthaler Ventures and Amgen Ventures. In conjunction with the funding, Rajeev Shah of RA Capital and Peter Tuxen Bisgaard of Novo Ventures (US) Inc have been added to Ra Pharma’s board of directors.

Continue

Cianna Medical raises $8 mln in venture, debt funding

By Chris Witkowsky — 7 months ago

Cianna Medical, which provides medical devices to improve quality of life for women with breast cancer, has raised $8 million, including $4 million from Novo Ventures, Fog City Fund, Saints Capital and Emergent Medical Partners. Cianna raised the balance of the funding in debt from GE Capital. The company will use the funding to support the launch of an FDA-cleared device that removes breast lesions.

Continue

Life sciences startup Unchained Labs grabs $25 mln

By Iris Dorbian — 12 months ago

Pleasanton, California-based life sciences tools startup Unchained Labs has closed $25 million in Series A funding. Novo Ventures, Canaan Partners and TPG Biotech led the round. Also, the company has acquired Optim, a multiplex protein stability platform for biologics. No financial terms were disclosed.

Continue

CoLucid Pharmaceuticals nabs $37.1 mln

By Iris Dorbian — 1 year ago

Durham, North Carolina-based CoLucid Pharmaceuticals, which develops oral lasmiditan that treats migraine headaches, has raised $37.1 million in Series C funding. TVM Capital Life Science led the round with participation from other investors Novo Ventures, Auriga Partners, Pappas Ventures, Domain Associates, Care Capital, Triathlon Medical Ventures and Pearl Street Ventures. Also, Dr. Luc Marengere of TVM Capital Life Science and Dr. Martin Edwards of Novo Ventures have been added to CoLucid’s board of directors.

Continue

Allakos secures $10 mln

By Angela Sormani — 1 year ago

Biotechnology company Allakos has secured an additional $10 million investment from current investors to fund the development of an additional therapeutic antibody. All of the company’s current investors participated including Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund.

Continue

VC-backed Otonomy files for IPO

By Iris Dorbian — 2 years ago

Otonomy said Monday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan Securities and BofA Merrill Lynch are serving as the lead underwriters. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases. Its backers include Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners.

Continue

Otonomy scores $49 mln Series D funds

By Iris Dorbian — 2 years ago

Otonomy said Wednesday that it has closed $49 million in Series D funding. The investors included Perceptive Advisors, Federated Kaufmann Funds, OrbiMed Advisors, Novo Ventures, TPG Biotech, Avalon Ventures, Domain Associates, RiverVest Venture Partners, Aperture Venture Partners and Osage University Partners. Based in San Diego, Calif., Otonomy is a biopharmaceutical company that develops treatments for ear disorders and diseases.

Continue

PanOptica snags $45 mln Series B funds

By Iris Dorbian — 2 years ago

PanOptica said Tuesday that it has closed up to $45 million in Series B funding. Novo Ventures and Third Rock Ventures led the round with participation from SV Life Sciences. Headquartered in Bernardsville, NJ, PanOptica is a biopharmaceutical firm focused on ophthalmology therapies.

Continue

Alios BioPharma attracts $41 mln

By Iris Dorbian — 2 years ago

Alios BioPharma has closed $41 million in Series B financing. Investors included Novo Ventures, SR One, Roche Venture Fund and Novartis Ventures. Based in South San Francisco, Alios BioPharma is a biotech firm focused on respiratory viral diseases.

Continue

Tobira Therapeutics Appoints Three Execs

By Angela Sormani — 3 years ago

Tobira Therapeutics, a developer of innovative antiretroviral therapies for HIV, has appointed three executives in the finance, clinical and pharmaceutical sciences functions. Caroline Loewy joins the company as executive vice president and chief financial officer, Jeff Enejosa, M.D., as senior director, clinical research, and Mark Menning as director, pharmaceutical sciences. Tobira has financial backing from […]

Continue

Alder BioPharma Bags $38M Round

By Jonathan Marino — 4 years ago

Alder BioPharmaceuticals closed a $38 million Series D round led by a new investor—Novo Ventures—and including existing Alder investors Sevin Rosen Funds, Ventures West, WRF Capital, H.I.G. Ventures, Delphi Ventures and TPG Biotech. Novo’s Peter Bisgaard will join Alder’s board as part of the deal. Alder BioPharma is based in Washington and is develops products […]

Continue